Influenza B virus NS1-truncated mutants: Live-attenuated vaccine approach

Rong Hai, Luis Martínez-Sobrido, Kathryn A. Fraser, Juan Ayllon, Adolfo García-Sastre, Peter Palese

Research output: Contribution to journalArticle

79 Scopus citations

Abstract

Type B influenza viruses can cause substantial morbidity and mortality in the population, and vaccination remains by far the best means of protection against infections with these viruses. Here, we report the construction of mutant influenza B viruses for potential use as improved live-virus vaccine candidates. Employing reverse genetics, we altered the NS1 gene, which encodes a type I interferon (IFN) antagonist. The resulting NS1 mutant viruses induced IFN and, as a consequence, were found to be attenuated in vitro and in vivo. The absence of pathogenicity of the NS1 mutants in both BALB/c and C57BL/6 PKR -/- mice was confirmed. We also provide evidence that influenza B virus NS1 mutants induce a self-adjuvanted immune response and confer effective protection against challenge with both homologous and heterologous B virus strains in mice.

Original languageEnglish (US)
Pages (from-to)10580-10590
Number of pages11
JournalJournal of virology
Volume82
Issue number21
DOIs
StatePublished - Nov 1 2008

Fingerprint Dive into the research topics of 'Influenza B virus NS1-truncated mutants: Live-attenuated vaccine approach'. Together they form a unique fingerprint.

  • Cite this

    Hai, R., Martínez-Sobrido, L., Fraser, K. A., Ayllon, J., García-Sastre, A., & Palese, P. (2008). Influenza B virus NS1-truncated mutants: Live-attenuated vaccine approach. Journal of virology, 82(21), 10580-10590. https://doi.org/10.1128/JVI.01213-08